Foralumab for Early Alzheimer's Disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have mild memory problems, confirmed by a special memory test.
- You have a PET scan showing amyloid plaques in your brain (a sign of Alzheimer's).
- You are not taking any immune-suppressing medicines or steroids.
- You have a family member or friend who can help you with study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This trial tests a vaccine that may help the immune system clear a protein linked to Alzheimer's disease. It is for people who do not have memory problems yet but have signs of the disease in their blood or brain scans.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.